JP7714323B2 - ベタヒスチンを含む鼻腔内組成物 - Google Patents

ベタヒスチンを含む鼻腔内組成物

Info

Publication number
JP7714323B2
JP7714323B2 JP2019541717A JP2019541717A JP7714323B2 JP 7714323 B2 JP7714323 B2 JP 7714323B2 JP 2019541717 A JP2019541717 A JP 2019541717A JP 2019541717 A JP2019541717 A JP 2019541717A JP 7714323 B2 JP7714323 B2 JP 7714323B2
Authority
JP
Japan
Prior art keywords
betahistine
pharmaceutical composition
dose
cps
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019541717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506930A (ja
JP2020506930A5 (enExample
Inventor
トマス マイヤー，
クリストファー ジョン ライト，
Original Assignee
オトラーヌム アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オトラーヌム アーゲー filed Critical オトラーヌム アーゲー
Publication of JP2020506930A publication Critical patent/JP2020506930A/ja
Publication of JP2020506930A5 publication Critical patent/JP2020506930A5/ja
Priority to JP2022017792A priority Critical patent/JP2022051872A/ja
Priority to JP2024000158A priority patent/JP2024019731A/ja
Application granted granted Critical
Publication of JP7714323B2 publication Critical patent/JP7714323B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019541717A 2017-02-02 2018-02-02 ベタヒスチンを含む鼻腔内組成物 Active JP7714323B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022017792A JP2022051872A (ja) 2017-02-02 2022-02-08 ベタヒスチンを含む鼻腔内組成物
JP2024000158A JP2024019731A (ja) 2017-02-02 2024-01-04 ベタヒスチンを含む鼻腔内組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762453931P 2017-02-02 2017-02-02
US62/453,931 2017-02-02
PCT/EP2018/052695 WO2018141922A1 (en) 2017-02-02 2018-02-02 Intranasal composition comprising betahistine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022017792A Division JP2022051872A (ja) 2017-02-02 2022-02-08 ベタヒスチンを含む鼻腔内組成物

Publications (3)

Publication Number Publication Date
JP2020506930A JP2020506930A (ja) 2020-03-05
JP2020506930A5 JP2020506930A5 (enExample) 2021-03-11
JP7714323B2 true JP7714323B2 (ja) 2025-07-29

Family

ID=61187302

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019541717A Active JP7714323B2 (ja) 2017-02-02 2018-02-02 ベタヒスチンを含む鼻腔内組成物
JP2022017792A Withdrawn JP2022051872A (ja) 2017-02-02 2022-02-08 ベタヒスチンを含む鼻腔内組成物
JP2024000158A Pending JP2024019731A (ja) 2017-02-02 2024-01-04 ベタヒスチンを含む鼻腔内組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022017792A Withdrawn JP2022051872A (ja) 2017-02-02 2022-02-08 ベタヒスチンを含む鼻腔内組成物
JP2024000158A Pending JP2024019731A (ja) 2017-02-02 2024-01-04 ベタヒスチンを含む鼻腔内組成物

Country Status (33)

Country Link
US (2) US10456386B2 (enExample)
EP (2) EP3698791B1 (enExample)
JP (3) JP7714323B2 (enExample)
KR (1) KR102653545B1 (enExample)
CN (2) CN118356397A (enExample)
AR (1) AR111699A1 (enExample)
AU (1) AU2018216970B2 (enExample)
CA (1) CA3051725A1 (enExample)
CL (1) CL2019002145A1 (enExample)
CO (1) CO2019008657A2 (enExample)
DK (2) DK3474850T3 (enExample)
EA (1) EA201991817A1 (enExample)
ES (2) ES2807798T3 (enExample)
FI (1) FI3698791T3 (enExample)
HR (2) HRP20201137T1 (enExample)
HU (2) HUE065336T2 (enExample)
IL (1) IL268353B2 (enExample)
LT (2) LT3698791T (enExample)
MA (1) MA46778B1 (enExample)
MX (1) MX381932B (enExample)
MY (1) MY196333A (enExample)
NZ (1) NZ755931A (enExample)
PH (1) PH12019501785B1 (enExample)
PL (2) PL3698791T3 (enExample)
PT (2) PT3698791T (enExample)
RS (2) RS65099B1 (enExample)
SA (1) SA519402324B1 (enExample)
SG (1) SG11201906980YA (enExample)
SI (2) SI3698791T1 (enExample)
TN (1) TN2019000220A1 (enExample)
TW (1) TWI760429B (enExample)
WO (1) WO2018141922A1 (enExample)
ZA (1) ZA201904955B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170532A1 (en) * 2017-03-22 2018-09-27 Franz, Lilian Ann Treatment method
US20230338279A1 (en) * 2020-04-14 2023-10-26 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Nasal spray formulation with moisturizing benefits
JP2023523410A (ja) * 2020-04-22 2023-06-05 サノタイズ リサーチ アンド ディベロップメント コープ． 上気道感染症を治療するための組成物および方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0397025A1 (en) 1989-05-08 1990-11-14 PRODOTTI FORMENTI S.r.l. [2-(2-pyridyl)ethyl]-methylamine salts
JP2011507895A (ja) 2007-12-21 2011-03-10 シェーリング−プラウ ヘルスケア プロダクツ，インコーポレイテッド オキシメタゾリンの増強された光安定化
JP2011520992A (ja) 2008-05-27 2011-07-21 ザ ユニバーシティー オブ メルボルン エウスタキオ管機能障害を有する哺乳動物の治療方法
WO2016049700A1 (en) 2014-10-03 2016-04-07 Lachesis Biosciences Pty Ltd Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397840B1 (enExample) 1977-07-22 1981-03-20 Cherqui Jean
JPH03287535A (ja) * 1990-03-31 1991-12-18 Bairon Boeki Kk プラノプロフェン水溶液
JP3203056B2 (ja) * 1992-08-13 2001-08-27 株式会社ティ・ティ・エス技術研究所 メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JPH10139667A (ja) * 1996-11-15 1998-05-26 Yoshitomi Pharmaceut Ind Ltd 水性液剤
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP3555598B2 (ja) 2001-06-27 2004-08-18 株式会社村田製作所 積層型インダクタ
JP2004196676A (ja) * 2002-12-16 2004-07-15 Rohto Pharmaceut Co Ltd 点鼻剤
JP4733333B2 (ja) * 2002-12-26 2011-07-27 ライオン株式会社 点鼻剤又は洗鼻剤
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
WO2005101979A2 (en) 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
AU2006202950A1 (en) * 2004-04-22 2006-10-19 Mor Research Applications Ltd. Methods and Compositions for Weight Management
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US20070111964A1 (en) * 2005-08-17 2007-05-17 Fleming And Company, Pharmaceuticals Vitamin B12 nasal spray and method of use
WO2007076140A2 (en) * 2005-12-23 2007-07-05 University Of Cincinnati Treatment methods employing histamine h3 receptor antagonists, including betahistine
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
EP2278999B1 (en) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
CN102216257B (zh) * 2008-10-08 2015-11-25 凯飞药业公司 Gaba偶联物及其使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0397025A1 (en) 1989-05-08 1990-11-14 PRODOTTI FORMENTI S.r.l. [2-(2-pyridyl)ethyl]-methylamine salts
JP2011507895A (ja) 2007-12-21 2011-03-10 シェーリング−プラウ ヘルスケア プロダクツ，インコーポレイテッド オキシメタゾリンの増強された光安定化
JP2011520992A (ja) 2008-05-27 2011-07-21 ザ ユニバーシティー オブ メルボルン エウスタキオ管機能障害を有する哺乳動物の治療方法
WO2016049700A1 (en) 2014-10-03 2016-04-07 Lachesis Biosciences Pty Ltd Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Also Published As

Publication number Publication date
IL268353A (en) 2019-09-26
CL2019002145A1 (es) 2019-11-04
ZA201904955B (en) 2021-05-26
EA201991817A1 (ru) 2020-01-27
KR102653545B1 (ko) 2024-04-04
TW201831179A (zh) 2018-09-01
HRP20231706T1 (hr) 2024-03-15
MY196333A (en) 2023-03-24
HRP20201137T1 (hr) 2021-01-22
SI3474850T1 (sl) 2020-09-30
JP2020506930A (ja) 2020-03-05
TWI760429B (zh) 2022-04-11
MA46778A1 (fr) 2021-04-30
MA46778B1 (fr) 2022-08-31
KR20190116341A (ko) 2019-10-14
US20180214432A1 (en) 2018-08-02
RS60554B1 (sr) 2020-08-31
PT3698791T (pt) 2024-01-12
LT3698791T (lt) 2024-02-12
ES2807798T3 (es) 2021-02-24
EP3474850B1 (en) 2020-04-22
ES2969301T3 (es) 2024-05-17
TN2019000220A1 (en) 2021-01-07
US10456386B2 (en) 2019-10-29
CN110418643A (zh) 2019-11-05
WO2018141922A1 (en) 2018-08-09
RS65099B1 (sr) 2024-02-29
DK3474850T3 (da) 2020-08-03
EP3474850A1 (en) 2019-05-01
CO2019008657A2 (es) 2020-01-17
PH12019501785A1 (en) 2020-07-06
PT3474850T (pt) 2020-07-27
JP2022051872A (ja) 2022-04-01
SA519402324B1 (ar) 2023-03-16
SI3698791T1 (sl) 2024-05-31
AU2018216970B2 (en) 2023-12-21
IL268353B2 (en) 2023-10-01
NZ755931A (en) 2022-07-29
PL3698791T3 (pl) 2024-04-08
HUE065336T2 (hu) 2024-05-28
PL3474850T3 (pl) 2020-09-21
MX2019008961A (es) 2019-10-15
FI3698791T3 (fi) 2024-01-11
AU2018216970A1 (en) 2019-08-22
EP3698791A1 (en) 2020-08-26
CN118356397A (zh) 2024-07-19
CA3051725A1 (en) 2018-08-09
LT3474850T (lt) 2020-08-10
DK3698791T3 (da) 2024-01-15
US20200022963A1 (en) 2020-01-23
JP2024019731A (ja) 2024-02-09
SG11201906980YA (en) 2019-08-27
MX381932B (es) 2025-03-13
IL268353B1 (en) 2023-06-01
PH12019501785B1 (en) 2024-02-28
BR112019015687A2 (pt) 2020-04-28
AR111699A1 (es) 2019-08-14
HUE050829T2 (hu) 2021-01-28
EP3698791B1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
US11717571B2 (en) Intranasal epinephrine formulations and methods for the treatment of disease
EP2522365B1 (en) Compositions comprising azelastine and methods of use thereof
JP2024019731A (ja) ベタヒスチンを含む鼻腔内組成物
US20190209464A1 (en) Compositions, devices and methods for the treatment of alcohol use disorder
US20190365728A1 (en) Pharmaceutical composition comprising betahistine
CN110505873B (zh) 鼻内肾上腺素制剂及治疗疾病的方法
HK40001248B (en) Intranasal composition comprising betahistine
HK40001248A (en) Intranasal composition comprising betahistine
EA041383B1 (ru) Интраназальная композиция, включающая бетагистин
BR112019015687B1 (pt) Composição intranasal compreendendo beta-histina e seus usos
US20250241873A1 (en) Ketamine nasal spray formulation and methods of use
US20250262173A1 (en) Intranasal epinephrine formulations and methods of use
HK40121592A (en) Intranasal epinephrine formulations and methods for the treatment of disease
HK40018410A (en) Intranasal epinephrine formulations and methods for the treatment of disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230724

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230810

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250716

R150 Certificate of patent or registration of utility model

Ref document number: 7714323

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150